Alnylam comments on fda approval of leqvio®, the first sirna (rnai therapeutic) approved to reduce ldl-c

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today highlighted the significance of the u.s. food and drug administration's (fda) approval of leqvio® (inclisiran), the fourth small interfering rna (sirna) therapy (or rnai therapeutic) approved in the u.s., and the first and only to lower low-density lipoprotein cholesterol (also known as “bad cholesterol” or ldl-c). leqvio is indicated in the u.s. as an adjunct to diet an
ALNY Ratings Summary
ALNY Quant Ranking